Get the Stockscreener App
1.43
2.14%
+0.03
After Hours:
1.43
Ikena Oncology Inc stock is currently priced at $1.43, with a 24-hour trading volume of 179.77K.
It has seen a +2.14% increased in the last 24 hours and a +15.32% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.38 pivot point. If it approaches the $1.45 resistance level, significant changes may occur.
Previous Close:
$1.40
Open:
$1.42
24h Volume:
179.77K
Market Cap:
$69.01M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
-0.8412
EPS:
-1.7
Net Cash Flow:
$-80.16M
1W Performance:
+10.85%
1M Performance:
+15.32%
6M Performance:
-20.56%
1Y Performance:
-77.93%
1D Range:
$1.36
$1.43
52W Range:
$1.02
$7.38
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-273-8343
Address
645 Summer Street, Suite 101, Boston
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update - MarketBeat
MarketBeat
Research Analysts Offer Predictions for Ikena Oncology, Inc.'s Q2 2024 Earnings (NASDAQ:IKNA) - Defense World
Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) to Post Q2 2024 Earnings of ($0.26) Per Share, Wedbush Forecasts - Defense World
Defense World
Q2 2024 EPS Estimates for Ikena Oncology, Inc. Raised by Wedbush (NASDAQ:IKNA) - MarketBeat
MarketBeat
Ikena Oncology (NASDAQ:IKNA) Earns “Outperform” Rating from Wedbush - Defense World
Defense World
Ikena Oncology (NASDAQ:IKNA) Rating Reiterated by Wedbush - MarketBeat
MarketBeat
Ikena Oncology Inc Stock (IKNA) Financials Data
Ikena Oncology Inc (IKNA) Revenue 2024
IKNA reported a revenue (TTM) of $9.16 million for the quarter ending December 31, 2023, a -41.34% decline year-over-year.
Ikena Oncology Inc (IKNA) Net Income 2024
IKNA net income (TTM) was -$68.17 million for the quarter ending December 31, 2023, a +0.87% increase year-over-year.
Ikena Oncology Inc (IKNA) Cash Flow 2024
IKNA recorded a free cash flow (TTM) of -$80.16 million for the quarter ending December 31, 2023, a -6.11% decrease year-over-year.
Ikena Oncology Inc (IKNA) Earnings per Share 2024
IKNA earnings per share (TTM) was -$1.63 for the quarter ending December 31, 2023, a +14.66% growth year-over-year.
About Ikena Oncology Inc
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
0.77%
1.20%
Cap:
|
Volume (24h):